Today, let's look at Moore Capital Management, managed by billionaire Louis Moore Bacon.
Keep Reading →
September 17 - Hedge Funds, News - Comments
The Chinese calendar says 2013 is the year of the snake, but the market says it's the year of biotech.
Keep Reading →
September 17 - News - Comments
There are plenty of biotech companies that put all of their eggs in one basket these days.
Keep Reading →
September 16 - News - Comments
The last several months have been remarkably exciting in the biotech space.
Keep Reading →
September 11 - News - Comments
A year ago, Best Buy Co., Inc.
Keep Reading →
August 27 - News - Comments
Let's start with Digital Generation Inc (NASDAQ:DGIT).
Keep Reading →
August 19 - News - Comments
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
Keep Reading →
August 12 - News - Comments
Babe Ruth wasn't afraid to swing for the fences. That's how he became Major League Baseball's home run king for decades.
Keep Reading →
July 15 - News - Comments
Let's start with Fly Leasing Ltd (ADR) (NYSE:FLY).
Keep Reading →
July 15 - News - Comments
For the last few weeks, there has been a heated debate regarding the success or lack thereof from biotechnology company Amarin Corporation plc (ADR) (NASDAQ:AMRN)'s new product...
Keep Reading →
July 10 - News - Comments
"More means less." Amarin Corporation plc (ADR) (NASDAQ:AMRN) demonstrated this seemingly contradictory maxim today following its announcement of a new public offering.
Keep Reading →
July 9 - News - Comments
Today let's look at Passport Capital, founded by John Burbank in 2000 and known for combining macroeconomic analysis and fundamental research.
Keep Reading →
July 5 - Hedge Funds - Comments
While the analysis of peak sales and potential patient populations may be appealing to most, it costs a great deal of money to launch a new product with success.
Keep Reading →
July 1 - News - Comments
Just as we examine companies each week that may be rising past their fair value, we can also find companies potentially trading at bargain prices.
Keep Reading →
June 27 - News - Comments
Mark your calendars Amarin Corporation plc (ADR) (NASDAQ:AMRN) investors.
Keep Reading →
June 20 - News - Comments
Today, let's look at Moore Capital Management, managed by billionaire Louis Moore Bacon.
Keep Reading →
June 20 - Hedge Funds - Comments
Amarin Corporation plc (ADR) (NASDAQ:AMRN) has recently launched its primary product candidate Vascepa into the market.
Keep Reading →
June 10 - News - Comments
AstraZeneca plc (ADR) (NYSE:AZN) announced the acquisition of Omthera Pharmaceuticals Inc (NASDAQ:OMTH), a company that went public just last month (April 11).
Keep Reading →
June 10 - News - Comments
GlaxoSmithKline plc (ADR) (NYSE:GSK)'s diabetes drug Avandia causes heart issues. Or maybe it doesn't.
Keep Reading →
June 10 - News - Comments
It has been a rough year for Amarin Corporation plc (ADR) (NASDAQ:AMRN) and its long-term investors.
Keep Reading →
June 3 - News - Comments
The biotechnology sector is rapidly evolving, and what was a near-guarantee of success of getting a drug approved by the Food and Drug Administration 10 years ago is no longer...
Keep Reading →
June 3 - News - Comments
We've been speculating for almost a year that Amarin Corporation plc (ADR) (NASDAQ:AMRN) would be purchased by AstraZeneca plc (ADR) (NYSE:AZN).
Keep Reading →
May 29 - News - Comments
The company announced Tuesday after the close that it had set up an accelerated share repurchase agreement with Goldman Sachs Group, Inc.
Keep Reading →
May 24 - News - Comments
A study published in The New England Journal of Medicine testing omega-3 fatty acids -- commonly found in fish oil -- in patients with risk factors for cardiovascular disease ...
Keep Reading →
May 13 - News - Comments
It’s not just about offering a better drug, but it’s also about launching it at the right time in the market.
Keep Reading →
April 28 - News - Comments
In this series, we'll highlight four companies in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting...
Keep Reading →
March 27 - News - Comments
Some stocks take a pounding, but there's usually what they call a dead-cat bounce.
Keep Reading →
March 25 - News - Comments
Sequester or no sequester, the folks at the Food and Drug Administration look to be quite busy in 2013.
Keep Reading →
March 25 - News - Comments
Today, let's look at Passport Capital, which was founded by John Burbank in 2000 and known for combining macroeconomic analysis and fundamental research.
Keep Reading →
March 20 - Hedge Funds - Comments
Last year, a number of drugs received FDA approval.
Keep Reading →
March 14 - News - Comments
As cardinals gather to elect a new pope, the conclave uses a smokestack to communicate the deliberations.
Keep Reading →
March 14 - News - Comments
Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to discuss Amarin Corporation plc (ADR) (NASDAQ:AMRN) , a biotech that recently launched...
Keep Reading →
March 6 - News - Comments
The last year has been a stellar one for the biotechnology industry.
Keep Reading →
February 26 - News - Comments
All throughout Wall Street we keep hearing about Amarin Corporation plc (ADR) (NASDAQ:AMRN) being bought out by some type of Big Pharma company in the future. It's all rumors...
Keep Reading →
February 22 - News - Comments
OraSure Technologies, Inc. (NASDAQ:OSUR) announced its fourth-quarter results after the market closed on Wednesday.
Keep Reading →
February 9 - News - Comments
Today, let's look at Tocqueville Asset Management, which is a portfolio manager with a contrarian bent, believing that "the best investment results over time are achieved outside...
Keep Reading →
February 6 - Hedge Funds - Comments
After several days of focusing on the economy, investors have had their attention pulled squarely back on earnings season, and some of the news hasn't been as good as they had...
Keep Reading →
January 21 - News - Comments